Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

A Double-blind, Randomized 12-week Study to Evaluate the Safety and Efficacy of GSK189075 Tablets vs Pioglitazone in Treatment Naive Subjects With Type 2 Diabetes Mellitus

This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment naive patients with T2DM

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2
• Intervention / Treatment: Other: Placebo; Drug: GSK189075; Drug: pioglitazone

• Study Type: Interventional
• Enrollment (Actual): 334
• Phase: Phase 2

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, 1425
    • GSK Investigational Site
  • Cordoba, Argentina, X5002AOQ
    • GSK Investigational Site
  • Mendoza, Argentina, M5500CCG
    • GSK Investigational Site
  • Quilmes, Argentina, 1878
    • GSK Investigational Site
  • Tucuman, Argentina, 4000
    • GSK Investigational Site
  • Buenos Aires
    • Buenos Aries, Buenos Aires, Argentina, C1425AWC
      • GSK Investigational Site
    • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1012AAR
      • GSK Investigational Site
    • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1117ABH
      • GSK Investigational Site
  • Córdova
    • Cordoba, Córdova, Argentina, 5000
      • GSK Investigational Site
• Bulgaria
  • Pleven, Bulgaria, 5800
    • GSK Investigational Site
  • Plovdiv, Bulgaria, 4000
    • GSK Investigational Site
  • Sofia, Bulgaria, 1606
    • GSK Investigational Site
  • Sofia, Bulgaria, 1233
    • GSK Investigational Site
  • Varna, Bulgaria, 9010
    • GSK Investigational Site
• Chile
  • Región Metro De Santiago
    • Santiago, Región Metro De Santiago, Chile, 7500010
      • GSK Investigational Site
    • Santiago, Región Metro De Santiago, Chile, 7510605
      • GSK Investigational Site
• Costa Rica
  • San José, Costa Rica
    • GSK Investigational Site
• Czechia
  • Brno, Czechia, 625 00
    • GSK Investigational Site
  • Brno, Czechia, 662 50
    • GSK Investigational Site
  • Brno, Czechia, 624 00
    • GSK Investigational Site
  • Ceske Budejovice, Czechia, 370 87
    • GSK Investigational Site
  • Cheb, Czechia, 350 02
    • GSK Investigational Site
  • Havirov - Soumbrak, Czechia, 736 01
    • GSK Investigational Site
  • Olomouc, Czechia, 779 00
    • GSK Investigational Site
  • Prague, Czechia, 181 00
    • GSK Investigational Site
  • Praha 5, Czechia, 158 00
    • GSK Investigational Site
  • Praha 5, Czechia, 15030
    • GSK Investigational Site
  • Praha 5, Czechia, 155 00
    • GSK Investigational Site
  • Semily, Czechia, 513 01
    • GSK Investigational Site
  • Sumperk, Czechia, 78752
    • GSK Investigational Site
  • Usti nad Labem, Czechia, 40001
    • GSK Investigational Site
  • Znojmo, Czechia, 67035
    • GSK Investigational Site
• Germany
  • Berlin, Germany, 10787
    • GSK Investigational Site
  • Baden-Wuerttemberg
    • Bammental, Baden-Wuerttemberg, Germany, 69245
      • GSK Investigational Site
    • Kippenheim, Baden-Wuerttemberg, Germany, 77971
      • GSK Investigational Site
    • Mannheim, Baden-Wuerttemberg, Germany, 68161
      • GSK Investigational Site
    • Weinheim, Baden-Wuerttemberg, Germany, 69469
      • GSK Investigational Site
  • Bayern
    • Haag, Bayern, Germany, 83527
      • GSK Investigational Site
    • Hoehenkirchen-Siegertsbrunn, Bayern, Germany, 85635
      • GSK Investigational Site
  • Hessen
    • Lampertheim, Hessen, Germany, 68623
      • GSK Investigational Site
  • Niedersachsen
    • Damme, Niedersachsen, Germany, 49401
      • GSK Investigational Site
    • Hannover, Niedersachsen, Germany, 30161
      • GSK Investigational Site
    • Hildesheim, Niedersachsen, Germany, 31139
      • GSK Investigational Site
  • Nordrhein-Westfalen
    • Bergkamen, Nordrhein-Westfalen, Germany, 59192
      • GSK Investigational Site
  • Rheinland-Pfalz
    • Mainz, Rheinland-Pfalz, Germany, 55116
      • GSK Investigational Site
    • Rhaunen, Rheinland-Pfalz, Germany, 55624
      • GSK Investigational Site
    • Speyer, Rheinland-Pfalz, Germany, 67346
      • GSK Investigational Site
• Hungary
  • Budapest, Hungary, 1021
    • GSK Investigational Site
  • Budapest, Hungary, 1088
    • GSK Investigational Site
  • Budapest, Hungary, 1076
    • GSK Investigational Site
  • Budapest, Hungary, 1036.
    • GSK Investigational Site
  • Debrecen, Hungary, 4043
    • GSK Investigational Site
  • Erd, Hungary, 2030
    • GSK Investigational Site
  • Győr, Hungary, 9023
    • GSK Investigational Site
  • Miskolc, Hungary, 3501
    • GSK Investigational Site
  • Miskolc, Hungary, 3530
    • GSK Investigational Site
  • Mosonmagyaróvár, Hungary, 9200
    • GSK Investigational Site
  • Nyirtegyhaza, Hungary, 4400
    • GSK Investigational Site
  • Pécs, Hungary, 7623
    • GSK Investigational Site
  • Szentes, Hungary, 6600
    • GSK Investigational Site
  • Szigetvar, Hungary, 7900
    • GSK Investigational Site
  • Szombathely, Hungary, 9700
    • GSK Investigational Site
  • Veszprem, Hungary, 8200
    • GSK Investigational Site
  • Zalaegerszeg, Hungary, 8900
    • GSK Investigational Site
• India
  • Bangalore, India, 560 054
    • GSK Investigational Site
  • Bangalore, India, 560034
    • GSK Investigational Site
  • Bangalore, India, 560017
    • GSK Investigational Site
  • Kochi, India, 682026
    • GSK Investigational Site
  • Mumbai, India, 400007
    • GSK Investigational Site
  • New Delhi, India, 110065
    • GSK Investigational Site
  • Pune, India, 411004
    • GSK Investigational Site
• Latvia
  • Jelgava, Latvia, LV 3001
    • GSK Investigational Site
  • Limbazi, Latvia, LV 4001
    • GSK Investigational Site
  • Riga, Latvia, LV 1002
    • GSK Investigational Site
  • Riga, Latvia, LV1002
    • GSK Investigational Site
  • Riga, Latvia, LV 1012
    • GSK Investigational Site
  • Riga, Latvia, LV 1011
    • GSK Investigational Site
  • Riga, Latvia, LV1058
    • GSK Investigational Site
  • Talsi, Latvia, LV 3201
    • GSK Investigational Site
  • Tukums, Latvia, LV 3100
    • GSK Investigational Site
• Lithuania
  • Kaunas, Lithuania, LT-50009
    • GSK Investigational Site
  • Kaunas, Lithuania, LT-51270
    • GSK Investigational Site
  • Kaunas, Lithuania, LT-49335
    • GSK Investigational Site
  • Vilnius, Lithuania, LT-08661
    • GSK Investigational Site
  • Vilnius, Lithuania, LT-07156
    • GSK Investigational Site
• Mexico
  • Durango, Mexico, 34079
    • GSK Investigational Site
  • Mexico, Mexico, 14080
    • GSK Investigational Site
  • Mexico, Mexico, 03100
    • GSK Investigational Site
  • Baja California Norte
    • Tijuana, Baja California Norte, Mexico, 22320
      • GSK Investigational Site
  • Estado De México
    • Mexico City, Estado De México, Mexico, 14000
      • GSK Investigational Site
  • Nuevo León
    • Monterrey, Nuevo León, Mexico, 64460
      • GSK Investigational Site
• New Zealand
  • Auckland, New Zealand, 1701
    • GSK Investigational Site
  • Auckland, New Zealand, 1311
    • GSK Investigational Site
  • Hamilton, New Zealand, 2001
    • GSK Investigational Site
  • Rotorua, New Zealand, 3201
    • GSK Investigational Site
• Peru
  • Lima, Peru, Lima 1
    • GSK Investigational Site
  • Lima, Peru, Lima 29
    • GSK Investigational Site
• Poland
  • Bydgoszcz, Poland, 85-021
    • GSK Investigational Site
  • Grudziadz, Poland, 86-300
    • GSK Investigational Site
  • Lodz, Poland, 90-153
    • GSK Investigational Site
  • Porabka, Poland, 43-353
    • GSK Investigational Site
  • Siemianowice Slaskie, Poland, 41-103
    • GSK Investigational Site
  • Wroclaw, Poland, 50-349
    • GSK Investigational Site
• Puerto Rico
  • Ponce, Puerto Rico, 00717
    • GSK Investigational Site
• Romania
  • Brasov, Romania, 500334
    • GSK Investigational Site
  • Bucharest, Romania, 020045
    • GSK Investigational Site
  • Deva, Romania, 330084
    • GSK Investigational Site
  • Iasi, Romania, 700514
    • GSK Investigational Site
• Russian Federation
  • Moscow, Russian Federation, 115446
    • GSK Investigational Site
  • Moscow, Russian Federation, 125367
    • GSK Investigational Site
  • Moscow, Russian Federation, 117 036
    • GSK Investigational Site
  • Moscow, Russian Federation, 127411
    • GSK Investigational Site
  • St. Petersburg, Russian Federation, 197110
    • GSK Investigational Site
  • St.-Petersburg, Russian Federation, 194354
    • GSK Investigational Site
  • Tomsk, Russian Federation, 634009
    • GSK Investigational Site
  • Tumen, Russian Federation, 625023
    • GSK Investigational Site
  • Ufa, Russian Federation, 450083
    • GSK Investigational Site
• South Africa
  • Bellville, South Africa, 7530
    • GSK Investigational Site
  • Gauteng, South Africa, 1459
    • GSK Investigational Site
  • Orangegrove, Linksfield West, South Africa, 2192
    • GSK Investigational Site
  • Parow, South Africa, 7505
    • GSK Investigational Site
  • Roodepoort, South Africa, 1709
    • GSK Investigational Site
• United States
  • Arizona
    • Mesa, Arizona, United States, 85206
      • GSK Investigational Site
  • Florida
    • Hollywood, Florida, United States, 33023
      • GSK Investigational Site
    • Miami, Florida, United States, 33156
      • GSK Investigational Site
    • Saint Cloud, Florida, United States, 34769
      • GSK Investigational Site
  • Louisiana
    • Sunset, Louisiana, United States, 70584
      • GSK Investigational Site
  • Maryland
    • Oxon Hill, Maryland, United States, 20745
      • GSK Investigational Site
  • Nevada
    • Las Vegas, Nevada, United States, 89106
      • GSK Investigational Site
    • Las Vegas, Nevada, United States, 89128
      • GSK Investigational Site
    • Las Vegas, Nevada, United States, 89016
      • GSK Investigational Site
  • New Mexico
    • Albuquerque, New Mexico, United States, 87102
      • GSK Investigational Site
  • Ohio
    • Canal Fulton, Ohio, United States, 44614
      • GSK Investigational Site
  • South Carolina
    • Simpsonville, South Carolina, United States, 29681
      • GSK Investigational Site
  • Texas
    • San Antonio, Texas, United States, 78229
      • GSK Investigational Site
  • Virginia
    • Burke, Virginia, United States, 22015
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

• Subjects with a documented diagnosis of T2DM and have an HbA1c level at Visit 1 of ≥7.0% and ≤9.5% as measured by a central laboratory. Subjects with HbA1c <7.5% must have a fasting fingerstick glucose ≥7 mmol/L (126 mg/dL) at Week 0 prior to randomization.
• Subjects who are treatment-naïve and have not taken insulin, or any oral or injectable anti-diabetic medication in the past 3 months and have not taken a glucose lowering agent for ≥4 weeks at any time in the past, or Subjects who are newly diagnosed and treated with diet and exercise for a minimum of 6 weeks
• Subjects who are 18 to 70 years of age inclusive at the time of Screening.

• Females of non-childbearing and childbearing potential are eligible to participate as follows:

  • Women of childbearing potential must be willing to use one of the following contraception methods: intrauterine device, condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent for at least 30 days prior to the start of study medication, throughout the study and the follow-up visit. Note: use of oral contraceptives is not permitted.
  • Women of non-child bearing potential are defined as follows: females regardless of age, with functioning ovaries and who have a current documented tubal ligation [Hatcher, 2004] bilateral oophorectomy or total hysterectomy, or females who are post-menopausal).

(Post-menopausal is defined as after one year without menses with an appropriate clinical profile, e.g. age appropriate, >45 years, in the absence of hormone replacement therapy. In addition to the above criteria, if the post-menopausal status is still questionable, a blood sample should be drawn for simultaneous measurement of follicle stimulating hormone and estradiol; values considered to confirm the post-menopausal state are respectively: FSH >40 MIU/mL and estradiol <40pg/mL (<140 pmol/L)).

• Informed Consent: a signed and dated written consent must be obtained from the subject before any procedures are performed.

Exclusion Criteria:

• Metabolic Disease

  • Diagnosis of Type 1 diabetes mellitus.
  • History of ketoacidosis which has required hospitalization.
  • Thyroid disorder [TSH below the lower limit of the reference range (LLRR) of 0.4mIU/L or above the upper limit of the reference range (ULRR) of >5.5 mIU/L at Screening]. Hypothyroidism treated with the same dose and regimen of thyroid hormone replacement for at least 3 months prior to Screening is allowed.
  • BMI of <22 or >43 kg/m2.
  • Significant weight gain or loss (as defined as >5% of total body weight) in the 3 months prior to Screening.

• Diabetic Medication

  • Has taken insulin or any oral or injectable anti-diabetic medication ≥4 weeks at any time prior to screening.
  • Has taken insulin or any oral or injectable anti-diabetic medication within 3 months of screening.

• Cardiovascular Disease

  • Recent history or presence of clinically significant acute cardiovascular disease including:

    1. Documented myocardial infarction in the 6 months prior to Screening.
    2. Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery either planned and/or occurred in the 6 months prior to Screening.
    3. Unstable angina in the 6 months prior to Screening.
    4. Clinically significant supraventricular arrhythmias requiring medical therapy, or history of nonsustained or sustained ventricular tachycardia. Symptomatic valvular heart disease or valvular heart disease requiring therapy other than endocarditis prophylaxis.
    5. Congestive heart failure (CHF, New York Heart Association (NYHA) Class II to IV) requiring pharmacologic treatment. NYHA Class I may be included in accordance with the local prescribing information for pioglitazone.
    6. Blood pressure (BP) >150/100mmHg. If a subject is receiving permitted antihypertensive therapy, then they must be on stable dose(s) of therapy for at least 4 weeks prior to Screening.
    7. Has a QTc interval (Bazett's) ≥450msec at Screening on a single ECG or an average value from 3 ECGs taken 5 minutes apart (on local reading of ECG).
    8. Other clinically significant ECG abnormalities which, in the opinion of the investigator, may affect the interpretation of efficacy and safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity.
  • Fasting triglycerides ≥400mg/dL (4.56mmol/L) at Screening. If a subject is receiving permitted lipid-lowering therapy, then they must be on a stable dose(s) of therapy for at least 6 weeks prior to Screening. Niacin and bile acid sequestrants are prohibited.
• Hepatic Disease

Has a diagnosis of active hepatitis (hepatitis B surface antigen or hepatitis C antibody), or clinically significant hepatic enzyme elevation including:

Any one of the following enzymes greater than 2 times the upper limit of the reference range (ULRR) value at Screening.

• alanine transaminase (ALT).
• aspartate transaminase (AST).

• alkaline phosphatase (AP). Has a total bilirubin level that is >1.5 times the ULRR at Screening with the exception of suspected or confirmed Gilbert's disease.

  • Pancreatic Disease
• Secondary causes of diabetes:

• history of chronic or acute pancreatitis

  • Renal Disease
• Significant renal disease at Screening as manifested by:

Glomerular filtration rate (GFR) <60mL/min (as estimated from serum creatinine at Visit 1 and demographic data using the MDRD equation).For the MDRD equation, please refer to the study procedures manual.

Proteinuria of ≥1+ by urinary dipstick

• Recurrent genitourinary tract infections defined as ≥2 episodes of complicated or uncomplicated cystitis or pyelonephritis in the 6 months prior to Screening

• A positive qualitative urinary dipstick for leukocytes, red blood cells (RBC) or nitrites at Screening.

  • Concurrent Disease
• Has any concurrent condition or any clinically significant abnormality identified on the screening physical examination, laboratory tests (including blood electrolytes), electrocardiogram, including pulmonary, neurological or inflammatory diseases, which, in the opinion of the investigator, may affect the interpretation of efficacy and safety data, or which otherwise contraindicates participation in a clinical trial with a new chemical entity
• History of significant co-morbid diseases active in the 6 months prior to Screening (e.g., cholecystitis, acute pancreatitis, gastrointestinal disease, chronic diarrhea, etc.)

• Has a history of malignancy within the past five years [other than superficial squamous cell carcinoma which is non-invasive on pathology or basal cell carcinoma which is successfully treated with local excision] and cervical cancer in situ treated definitively at least 6 months prior to Screening

  • Concurrent Medication

• Is currently taking or has taken any of the following medications in the 8 weeks prior to Screening:

  1. Digoxin
  2. Warfarin and other oral anticoagulants (aspirin and non-steroidal anti-inflammatory drugs are permitted)
  3. Bile acid sequestrants
  4. Niacin (excluding routine vitamin supplementation)
  5. Antiobesity agents (including fat absorption blocking agents)
  6. Oral or injectable corticosteroids (inhaled and intranasal corticosteroids are permitted)
  7. Loop diuretics
  8. Monoamine oxidase inhibitors and tricyclic amines
  9. Antiretroviral drugs
  10. St John's Wort

  11. Oral chromium

      • Pregnancy & Breast Feeding

• Is currently lactating or pregnant

  • Other
• Current smoker who is unable to abstain from smoking while in the clinic at each visit
• Has a history of alcohol or substance abuse within the past year at Screening or alcohol or substance abuse during treatment, as determined by the investigator:
• Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.
• Has an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint of beer or 1 measure of spirits or 1 glass of wine
• Has participated in any study with an investigational or marketed drug in the 3 months prior to Screening
• In the opinion of the investigator has a risk of non-compliance with study procedures, or cannot read, understand, or complete study related materials, particularly the informed consent
• Known allergy to any of the tablet excipients, or history of drug or other allergy, which, in the opinion of the responsible study physician

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Arm 2; Placebo	Other: Placebo; Placebo Comparator
Experimental: Arm 1; GSK189075	Drug: GSK189075; Experimental Drug
Other: Arm 3; pioglitazone (active control)	Drug: pioglitazone; Active Control

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline (Week 0) in Glycosylated Hemoglobin (HbA1c) (%) at Week 12	Fasted blood samples for HbA1c were collected at Baseline and Week 12. Participants were required to fast for at least 8 hours prior to laboratory samples and were told not to take the morning dose of study medication on these visit days and to refrain from eating until instructed to do so by study personnel in the clinic. When the participant had not fasted, the participant was rescheduled to return to the clinic to have a fasted sample taken. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values. Only those participants with a value at Baseline and at Week 12 (after Last Observation Carried Forward [LOCF]) were used for this analysis. Adjusted mean is presented as least square mean.	Baseline (Week 0) and Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in HbA1c (%) at Weeks 4 and 8	Fasted blood samples for HbA1c were collected at Baseline and Weeks 4 and 8. Participants were required to fast for at least 8 hours prior to laboratory samples and were told not to take the morning dose of study medication on these visit days and to refrain from eating until instructed to do so by study personnel in the clinic. When the participant had not fasted, the participant was rescheduled to return to the clinic to have a fasted sample taken. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Baseline (Week 0) and Week 4 and Week 8
Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG) at Weeks 4, 8 and 12	Fasted blood samples for FPG were collected up to Week 12. Participants were required to fast for at least 8 hours prior to laboratory samples and were told not to take the morning dose of study medication on these visit days and to refrain from eating until instructed to do so by study personnel in the clinic. When the participant had not fasted, the participant was rescheduled to return to the clinic to have a fasted sample taken. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Baseline (Week 0) and Week 4, Week 8 and Week 12
Change From Baseline to Week 12 in Fructosamine	Fasted blood samples for fructosamine were collected up to Week 12. Participants were required to fast for at least 8 hours prior to laboratory samples and were told not to take the morning dose of study medication on these visit days and to refrain from eating until instructed to do so by study personnel in the clinic. When the participant had not fasted, the participant was rescheduled to return to the clinic to have a fasted sample taken. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Baseline (Week 0) to Week 12
Change From Baseline to Week 12 in Fasting Insulin	Fasted blood samples for insulin were collected up to Week 12. Participants were required to fast for at least 8 hours prior to laboratory samples and were told not to take the morning dose of study medication on these visit days and to refrain from eating until instructed to do so by study personnel in the clinic. When the participant had not fasted, the participant was rescheduled to return to the clinic to have a fasted sample taken. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Baseline (Week 0) to Week 12
Number of Participants at Week 12 With: HbA1c <= 6.5%, HbA1c <7.0%; FPG <7 Mmo/L, FPG <7.8 mmol/L; FPG <5.5 mmol/L; a Decrease From Baseline of HbA1c >= 0.7%; a Decrease From Baseline of FPG ≥1.7 mmol/L	Fasted blood samples for HbA1c were collected at Week 12. Participants were required to fast for at least 8 hours prior to laboratory samples and were told not to take the morning dose of study medication on these visit days and to refrain from eating until instructed to do so by study personnel in the clinic. When the participant had not fasted, the participant was rescheduled to return to the clinic to have a fasted sample taken. Number of participants at Week 12 with: HbA1c <= 6.5%, HbA1c <7.0%; FPG <7 mmo/L (126 milligram/deciliter [mg/dL]), FPG <7.8 mmol/L (140 mg/dL); FPG <5.5 mmol/L (100 mg/dL); a decrease from Baseline of HbA1c >= 0.7%; a decrease from Baseline of FPG ≥1.7 mmol/L (30 mg/dL) are presented.	Week 12
Percent Change From Baseline in Lipid Parameters at Weeks 4, 8 and 12(Triglycerides [TG], Total Cholesterol [TC], Low-density Lipoprotein Cholesterol [LDL-C] and High-density Lipoprotein Cholesterol [HDL-C])	Fasted samples for TC, LDL-C, HDL-C and TG were collected at Week 12. When the participant had not fasted, the participant was rescheduled to return to the clinic to have a fasted sample taken. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values. Percent Change based on log-transformed data: 100*(exponentiated(mean change on log scale)-1)	Baseline (Week 0) and Week 4, Week 8 and Week 12
Change From Baseline to Week 12 in Body Weight	Weight of participants was measured from Baseline (Week 0) to Week 12 and recorded in the case report form (CRF). Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Baseline (Week 0) to Week 12
Change From Baseline to Week 12 in Waist Circumference	Waist circumference of participants was measured from Baseline (Week 0) to Week 12 and recorded in the CRF. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Baseline (Week 0) to Week 12
Change From Baseline in 24-hour Percent of Filtered Glucose Excreted in Urine	A 24-hour urine collection was obtained from all participants at Baseline (Week 0) and Week 12 to measure glucose. Participants were provided with urine collection bottles and cooler prior to these visits and instructed that the urine collections must be kept cold and dropped off at the clinic prior to or at the scheduled visits. Site staff queried participants to determine whether the sample represented a full 24-hour collection. The total volume and the sample date and time were recorded. The entire 24-hour urine collection was well mixed in one container and a urine aliquot obtained. Samples were assayed for glucose. The 24-hour collections were used to derive 24-hour urine glucose excretion corrected for filtered load. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Baseline (Week 0) and Week 12 (24-hour urine collection)
Change From Baseline in Plasma Glucose Area Under the Curve (AUC) During a 2-hour Oral Glucose Tolerance Test (OGTT)	Post-prandial assessments of glucose were performed at Baseline (Week 0) and at Week 12 using a 2-hour OGTT in a subgroup of participants at selected sites who agreed to participate. Participants were required to fast for at least 8 hours prior to the test. Seventy-five (75) g of standard oral glucose solution was administered 15 minutes after the morning administration of study medication (Week 12) and in the place of breakfast at Week 0 (i.e., at Week 0 the OGTT was completed prior to administration of study medication). Time "0" started when the participants drank the glucose solution. Blood samples were collected at the following times relative to the administration of oral glucose: -30 min (pre-glucose), -20 min (pre-glucose), 20 min, 30 min, 1 hour, 1.5 hour and 2 hour post glucose administration. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Baseline (Week 0) and Week 12 (0 to 2 hour OGTT)
Change From Baseline in Insulin AUC During a 2-hour OGTT	Post-prandial assessments of insulin were performed at Baseline (Week 0) and at Week 12 using a 2-hour OGTT in a subgroup of participants at selected sites who agreed to participate. Participants were required to fast for at least 8 hours prior to the test. Seventy-five (75) g of standard oral glucose solution was administered 15 minutes after the morning administration of study medication (Week 12) and in the place of breakfast at Week 0 (i.e., at Week 0 the OGTT was completed prior to administration of study medication). Time "0" started when the participants drank the glucose solution. Blood samples were collected at the following times relative to the administration of oral glucose: -30 min (pre-glucose), -20 min (pre-glucose), 20 min, 30 min, 1 hour, 1.5 hour and 2 hour post glucose administration. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Baseline (Week 0) and Week 12 (0 to 2-hour OGTT)
Change From Baseline in C-peptide AUC During a 2-hr OGTT	Post-prandial assessments of C-peptide were performed at Baseline (Week 0) and at Week 12 using a 2-hour OGTT in a subgroup of participants at selected sites who agreed to participate. Participants were required to fast for at least 8 hours prior to the test. Seventy-five (75) g of standard oral glucose solution was administered 15 minutes after the morning administration of study medication (Week 12) and in the place of breakfast at Week 0 (i.e., at Week 0 the OGTT was completed prior to administration of study medication). Time "0" started when the participants drank the glucose solution. Blood samples were collected at the following times relative to the administration of oral glucose: -30 min (pre-glucose), -20 min (pre-glucose), 20 min, 30 min, 1 hour, 1.5 hour and 2 hour post glucose administration. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Baseline (Week 0) and Week 12 (0 to 2 hour OGTT)
Number of Participants With On-therapy Adverse Events (AE) and Serious Adverse Events (SAE)	AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.	Up to 12 weeks
Number of Participants With On-therapy Hypoglycemia	Hypoglycemia is low blood glucose or low blood sugar. Hypoglycemic events were collected separately and reported separately from AE, including supplemental data which were not collected for AE. However, any hypoglycemic event which met the criteria for a SAE was included in the SAE summaries. The number of participants in each group that experienced a hypoglycemic event was summarized by frequency of the events.	Up to 14 weeks
Number of Participants With Change From Baseline Vital Signs of Potential Clinical Concern	Vital signs included heart rate and blood pressure. Heart rate and blood pressure were taken before blood draws were performed. Participants were asked to refrain from smoking for at least 30 minutes prior to vital sign measurements. Heart rate and blood pressure was measured pre-dose in duplicate at the specified visits, after the participant had been lying quietly for 5 minutes, and then in duplicate 3 minutes after standing up. Heart rate was measured at the same time as blood pressure using the standardized blood pressure equipment that was provided. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Up to 14 weeks
Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Concern	Full 12-lead ECGs were recorded at screening, Baseline (Week 0), Week 4, Week 12 or early withdrawal, and Week 14 (Follow-up) using an ECG machine that automatically calculated the heart rate and measured the PR, QRS, QT and corrected QT (QTc) intervals. All 12-lead ECGs were read locally by the Investigator or his/her designate and were forwarded electronically to the central reader for interpretation. If the QTc was >500 milliseconds (msec) on the locally read ECG recording, an additional 2 ECG recordings at 10 minute intervals were made at that visit. If the average QTc for the 3 recordings was >500 msec, the participant was withdrawn from the study.	Up to Early withdrawal (Between Week 12 and Week 14)
Number of Participants With Change From Baseline in Standard Laboratory Parameters of Potential Clinical Concern	Participants were instructed to fast for at least 8 hours prior to all study visits for the collection of laboratory samples. An additional fasting blood sample (serum and plasma) was drawn at Week 0, Week 4, Week 6 and Week 12 or at early withdrawal (up to 14 weeks) and kept in long-term storage for future testing of biomarkers for diabetes and complications of the disease. Baseline was Week 0. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.	Up to 14 weeks

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Sykes AP, O'Connor-Semmes R, Dobbins R, Dorey DJ, Lorimer JD, Walker S, Wilkison WO, Kler L. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015 Jan;17(1):94-7. doi: 10.1111/dom.12391. Epub 2014 Nov 3.

Study record dates

Study Major Dates

• Study Start (Actual): January 23, 2007
• Primary Completion (Actual): February 14, 2008
• Study Completion (Actual): February 14, 2008

Study Registration Dates

• First Submitted: January 24, 2007
• First Submitted That Met QC Criteria: July 10, 2007
• First Posted (Estimate): July 12, 2007

Study Record Updates

• Last Update Posted (Actual): December 6, 2017
• Last Update Submitted That Met QC Criteria: November 2, 2017
• Last Verified: September 1, 2017

More Information

Terms related to this study

• Keywords: HbA1c; Diabetes mellitus; Pioglitazone
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Pioglitazone
• Other Study ID Numbers: KG2105255